Mortality (Latin: mortalitas, from mors = death) in clinical research and epidemiology refers to the death rate of a defined population within a specific period. As a study endpoint, all-cause mortality or disease-specific mortality (e.g., cardiovascular mortality) is considered one of the hardest and most regulatorily significant endpoints of a clinical trial. In contrast to surrogate endpoints, mortality requires no assumptions about biological mechanisms or causal chains of action—the clinical benefit is directly measurable, clearly documentable, and immediately understandable for patients, regulators, and reimbursement authorities. For this reason, mortality reduction is considered the gold standard among clinical endpoints.
Mortality as a Clinical Endpoint
In clinical research, a distinction is made between various mortality endpoints, which are used depending on the indication and study design:
- All-Cause Mortality: Records all deaths regardless of the cause. It is considered the most objective and unbiased endpoint, as no adjudication effort is required for the cause of death. Preferred by regulators in long-term cardiology and oncology studies with a sufficiently high event rate.
- Disease-Specific Mortality: Considers only deaths attributable to the disease under investigation (e.g., cardiovascular death, cancer-related death). It requires independent adjudication by a blinded Endpoint Adjudication Committee. Since the classification of the cause of death leaves room for interpretation, clear adjudication rules and complete clinical documentation are essential.
- 30-Day Mortality / 90-Day Mortality: Time-limited mortality measures used as primary endpoints, particularly in intensive care medicine, surgical studies, and acute diseases. The short observation period significantly reduces the follow-up effort.
- Overall Survival (OS): The time from the date of randomization to death from any cause. A standard endpoint in oncology pivotal trials and methodologically anchored in survival analysis.
Statistical Analysis of Mortality
Mortality data in clinical trials are typically evaluated using survival analysis methods. The Kaplan-Meier method visualizes the survival function graphically and enables a descriptive comparison between treatment groups. The log-rank test is frequently used for formal statistical comparison. The Cox proportional hazards model allows for adjustment for covariates and provides the hazard ratio as an effect measure—a central measure for the relative risk of death between two groups.
Important methodological aspects include the correct handling of censored observations—patients who reach the end of the study alive or withdraw prematurely—as well as the assessment of the proportional hazards assumption. Additionally, consideration must be given to competing risks, adequate sample size planning based on the expected event rate (event-driven design), and the presentation of landmark analyses and Restricted Mean Survival Time (RMST) as alternative effect measures when the proportionality assumption is violated.
Regulatory Significance
Mortality as a primary endpoint holds the highest regulatory status because it is directly clinically significant and requires no surrogate assumptions. In indications with high mortality (oncology, heart failure, sepsis), the EMA and BfArM prefer studies with mortality or survival endpoints over surrogate endpoints. For the benefit assessment according to Section 35a SGB V by the Federal Joint Committee (G-BA), mortality reduction is considered the highest category of added benefit. Medicinal products that demonstrate a statistically significant and clinically relevant reduction in all-cause mortality regularly receive the highest added benefit (major), which directly impacts reimbursement price negotiations with the GKV-Spitzenverband.
Relevance for clinical trials
Studies with mortality endpoints typically require large patient numbers, long durations, and a robust safety monitoring framework, including an independent Data Safety Monitoring Board (DSMB). Full-service CROs like mediconomics support sponsors in statistical study planning for mortality-based endpoints, the establishment and management of DSMBs, adjudication planning for deaths, and the regulatorily compliant documentation and reporting of deaths as serious adverse events in accordance with ICH E6(R3) and EU Regulation No. 536/2014.
Frequently Asked Questions (FAQ)
What is the difference between mortality and morbidity?
Mortality refers to the death rate—the occurrence of deaths in a population. Morbidity refers to the frequency of disease—the occurrence of illnesses, complications, or events without a necessarily fatal outcome. In composite endpoints (MACE: Major Adverse Cardiovascular Events), mortality and morbidity are often combined, which facilitates sample size planning as events occur more frequently than deaths alone.
When is all-cause mortality preferred over disease-specific mortality?
All-cause mortality is preferred when there is a risk that an intervention reduces death from one cause but increases death from other causes (e.g., antiarrhythmic drugs that reduce sudden cardiac death but may increase all-cause mortality). In such indications, regulators explicitly demand all-cause mortality data to obtain a complete safety profile and to identify undesirable compensatory effects.
How are deaths documented in a clinical trial?
Every death is considered a serious adverse event (SAE) and must be reported within 7 days (unexpected deaths with a possible relationship to the study medication) or 15 days in accordance with ICH E6(R3) and EU Regulation No. 536/2014. Detailed documentation of the cause of death, the timeline, the accompanying circumstances, and a causal assessment by the investigator regarding a possible relationship with the study medication are mandatory. This documentation forms the basis for subsequent adjudication and for inquiries from authorities during the marketing authorization process.
Regulatory References
- ICH E9 – Statistical Principles for Clinical Trials (1998): Endpoint definition, survival analysis
- ICH E9(R1) – Addendum on Estimands (2019): Handling of deaths as an intercurrent event
- EMA Guideline on the Evaluation of Anticancer Medicinal Products in Man (EMA/CHMP/205/95 Rev. 6, 2019): OS as a primary endpoint
- EU Regulation No. 536/2014 (CTR) Art. 42: SAE reporting obligations including deaths
- G-BA Rules of Procedure Section 35a SGB V: Mortality reduction as the highest category of added benefit in early benefit assessment
- ICH E6(R3) – Good Clinical Practice (2023): Requirements for SAE reporting, documentation, and source data quality for deaths